RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): Non bis in idem?

Supportive Care in Cancer

Volumn 19, Issue 12, 2011, Pages 2035-2040

  Van Den Wyngaert, Tim ^a   Wouters, Kristien ^a   Huizing, Manon T ^a   Vermorken, Jan B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

AMG162; Bisphosphonates; Denosumab; Jaw; ONJ; Osteonecrosis; Zoledronic acid

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; BREAST CANCER; DRUG SAFETY; HEALING; HUMAN; JAW OSTEONECROSIS; LUNG NON SMALL CELL CANCER; META ANALYSIS; MUCOSAL HEALING; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; JAW; MALE; OSTEONECROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANK LIGAND;

EID: 83555160903     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-1061-0     Document Type: Article

References (30)

1. T Van den Wyngaert MT Huizing JB Vermorken 2006 Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol 17 1197 1204 16873439 10.1093/annonc/mdl294 (Pubitemid 44288209)
2. SL Ruggiero TB Dodson LA Assael R Landesberg RE Marx B Mehrotra 2009 American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update J Oral Maxillofac Surg 67 2 12 19371809
3. T Van den Wyngaert MT Huizing E Fossion JB Vermorken 2009 Bisphosphonates in oncology: rising stars or fallen heroes Oncologist 14 181 191 19179412 10.1634/theoncologist.2008-0209
4. MA Dimopoulos E Kastritis C Bamia I Melakopoulos D Gika M Roussou M Migkou E Eleftherakis-Papaiakovou D Christoulas E Terpos A Bamias 2009 Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid Ann Oncol 20 117 120 18689864 10.1093/annonc/mdn554 1:STN:280:DC%2BD1M%2Fns12hug%3D%3D
5. CI Ripamonti M Maniezzo T Campa E Fagnoni C Brunelli G Saibene C Bareggi L Ascani E Cislaghi 2009 Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan Ann Oncol 20 137 145 18647964 10.1093/annonc/mdn526 1:STN:280:DC%2BD1M%2Fns1ygug%3D%3D
6. PJ Bekker DL Holloway AS Rasmussen R Murphy SW Martin PT Leese GB Holmes CR Dunstan AM DePaoli 2004 A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 19 1059 1066 15176987 10.1359/JBMR.040305 1:CAS:528:DC%2BD2cXlvFWrtr0%3D (Pubitemid 41110556)
7. European Medicines Agency (2010) Prolia: EPAR-public assessment report. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public- assessment-report/human/001120/WC500093529.pdf. Accessed 23 September 2010
8. Food and Drug Administration (2010) Approval letter denosumab. Available at http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/125320s000Approv.pdf. Accessed 23 September 2010
9. Food and Drug Administration (2010) Risk evaluation and mitigation strategy (REMS) BL 125320 Prolia (denosumab). Available at http://www.fda.gov/ downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM214383.pdf. Accessed 23 September 2010
10. W Cochran 1954 The combination of estimates from different experiments Biometrics 10 101 129 10.2307/3001666
11. Woodward M (2005) Epidemiology: study design and analysis. Chapman & Hall, Boca Raton
12. A Stopeck J Body Y Fujiwara A Lipton G Steger M Viniegra BA Fan R Dansey S Jun 2009 Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study Eur J Cancer Suppl 7 2 3 10.1016/S1359-6349(09)72028-2
13. D Henry R von Moos S Vadhan-Raj V Hungria A Spencer V Hirsh J Wang S Jun H Yeh R Dansey 2009 A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma Eur J Cancer Suppl 7 12 10.1016/S1359-6349(09)72055-5
14. K Fizazi M Carducci M Smith R Damião J Brown L Karsh P Milecki H Wang R Dansey C Goessl 2010 A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer J Clin Oncol 28 LCB4507
15. A Lipton A Stopeck R von Moos D Henry G Richardson G Rodriguez H Bourgeois C Ke S Jun R Dansey 2010 A meta-analysis of results from two randomized, double-blind studies of denosumab versus zoledronic acid (ZA) for treatment of bone metastases J Clin Oncol 28 9015
16. A Lipton S Siena M Rader B Bilynskyy M Viniegra G Richardson P Beuzeboc M Clemens C Ke S Jun 2010 Comparison of denosumab versus zoledronic acid (ZA) for treatment of bone metastases in advanced cancer patients: an integrated analysis of 3 pivotal trials Ann Oncol 21 1249P
17. PP Major R Cook 2002 Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints Am J Clin Oncol 25 S10 S18 12562046 10.1097/00000421-200212001-00003 (Pubitemid 35476854)
18. MH Cohen R Dagher DJ Griebel A Ibrahim A Martin NS Scher GH Sokol GA Williams R Pazdur 2002 U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid Oncologist 7 393 400 12401901 10.1634/theoncologist.7-5-393 1:CAS:528:DC%2BD38XptVOgtL8%3D
19. AO Hoff BB Toth K Altundag MM Johnson CL Warneke M Hu A Nooka G Sayegh V Guarneri K Desrouleaux J Cui A Adamus RF Gagel GN Hortobagyi 2008 Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J Bone Miner Res 23 826 836 18558816 10.1359/jbmr.080205 1:CAS:528:DC%2BD1cXnvVGjs70%3D (Pubitemid 351768801)
20. S Hoefert I Schmitz A Tannapfel H Eufinger 2010 Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings Clin Oral Investig 14 271 284 19536569 10.1007/s00784-009-0300-6
21. Tricker N, Dixon R, Garetto L (2002) Cortical bone turnover and mineral apposition in dentate bone mandible. In: Garetto L, Turner C, Duncan R, Burr D (eds) Bridging the gap between dental and orthopaedic implants. Indiana University School of Dentistry, Indianapolis, pp 226-227
22. SS Huja SA Fernandez KJ Hill Y Li 2006 Remodeling dynamics in the alveolar process in skeletally mature dogs Anat Rec A Discov Mol Cell Evol Biol 288 1243 1249 17075846 (Pubitemid 44901865)
23. A Bamias E Kastritis C Bamia LA Moulopoulos I Melakopoulos G Bozas V Koutsoukou D Gika A Anagnostopoulos C Papadimitriou E Terpos MA Dimopoulos 2005 Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 23 8580 8587 16314620 10.1200/JCO.2005.02.8670 (Pubitemid 46211499)
24. CL Estilo CH Van Poznak T Wiliams GC Bohle PT Lwin Q Zhou ER Riedel DL Carlson H Schoder A Farooki M Fornier JL Halpern SJ Tunick JM Huryn 2008 Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy Oncologist 13 911 920 18695259 10.1634/theoncologist.2008-0091
25. K Vahtsevanos A Kyrgidis E Verrou E Katodritou S Triaridis CG Andreadis I Boukovinas GE Koloutsos Z Teleioudis K Kitikidou P Paraskevopoulos K Zervas K Antoniades 2009 Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw J Clin Oncol 27 5356 5362 19805682 10.1200/JCO.2009.21.9584 1:CAS:528:DC%2BD1MXhsFKkt7rF
26. K Fizazi A Lipton X Mariette JJ Body Y Rahim JR Gralow G Gao L Wu W Sohn S Jun 2009 Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates J Clin Oncol 27 1564 1571 19237632 10.1200/JCO.2008.19.2146 1:CAS:528:DC%2BD1MXltVOhtr0%3D
27. RE Coleman P Major A Lipton JE Brown KA Lee M Smith F Saad M Zheng YJ Hei J Seaman R Cook 2005 Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid J Clin Oncol 23 4925 4935 15983391 10.1200/JCO.2005.06.091 1:CAS:528:DC%2BD2MXpsFWmtL4%3D (Pubitemid 46223998)
28. T Van den Wyngaert MT Huizing JB Vermorken 2007 Osteonecrosis of the jaw related to the use of bisphosphonates Curr Opin Oncol 19 315 322 17545793 10.1097/CCO.0b013e32819f820b (Pubitemid 46883519)
29. T Van den Wyngaert T Claeys MT Huizing JB Vermorken E Fossion 2009 Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome Ann Oncol 20 331 336 18953067 10.1093/annonc/mdn630
30. BJ Edwards M Gounder JM McKoy I Boyd M Farrugia C Migliorati R Marx S Ruggiero M Dimopoulos DW Raisch S Singhal K Carson E Obadina S Trifilio D West J Mehta CL Bennett 2008 Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw Lancet Oncol 9 1166 1172 19038763 10.1016/S1470-2045(08)70305-X